These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 8167090

  • 1. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT, Davis LP.
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [Abstract] [Full Text] [Related]

  • 2. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D, Spaas P, Specenier P.
    Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
    [Abstract] [Full Text] [Related]

  • 3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 4. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK.
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [Abstract] [Full Text] [Related]

  • 5. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT, McEwan AJ.
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [Abstract] [Full Text] [Related]

  • 6. Bone pain palliation with 85Sr therapy.
    Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P.
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [Abstract] [Full Text] [Related]

  • 7. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW, Xie P, Deng HF.
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [Abstract] [Full Text] [Related]

  • 8. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A, Dafermou A, Giganti M, Colamussi P, Pizzocaro C, Bestagno M, Italian Association of Nuclear Medicine (AINM).
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [Abstract] [Full Text] [Related]

  • 9. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA.
    Urol Int; 2006 Mar; 77(1):50-6. PubMed ID: 16825816
    [Abstract] [Full Text] [Related]

  • 10. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB, Lee CA.
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases.
    Zorga P, Birkenfeld B, Listewnik MH, Piwowarska-Bilska H.
    Ann Acad Med Stetin; 2011 Apr; 57(1):49-53; discussion 53. PubMed ID: 22593991
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA.
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [Abstract] [Full Text] [Related]

  • 13. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
    Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ.
    J Clin Oncol; 2005 Nov 01; 23(31):7904-10. PubMed ID: 16258090
    [Abstract] [Full Text] [Related]

  • 14. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ.
    J Nucl Med; 2000 Jun 01; 41(6):1021-4. PubMed ID: 10855628
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
    Kiselev EN, Korytova LI, Karelin MI.
    Vopr Onkol; 2005 Jun 01; 51(6):689-91. PubMed ID: 17037036
    [Abstract] [Full Text] [Related]

  • 16. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan 01; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 17. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, Reed NS, Russell JM, Yardley J.
    Semin Oncol; 1993 Jun 01; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract] [Full Text] [Related]

  • 18. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
    Hansen DV, Holmes ER, Catton G, Thorne DA, Chadwick DH, Schmutz DA.
    Am Fam Physician; 1993 Jun 01; 47(8):1795-800. PubMed ID: 7684554
    [Abstract] [Full Text] [Related]

  • 19. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL, Powe JE, Porter AT.
    J Nucl Med; 1992 Jul 01; 33(7):1316-23. PubMed ID: 1613572
    [Abstract] [Full Text] [Related]

  • 20. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 01; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.